Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C36H59N5O2 |
| Molecular Weight | 593.886 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCCCCCC(=O)NCCCCON1C(CCCC)=NC2=C1C3=CC=CC=C3N=C2N
InChI
InChIKey=RRTPWQXEERTRRK-UHFFFAOYSA-N
InChI=1S/C36H59N5O2/c1-3-5-7-8-9-10-11-12-13-14-15-16-17-18-19-27-33(42)38-28-22-23-29-43-41-32(26-6-4-2)40-34-35(41)30-24-20-21-25-31(30)39-36(34)37/h20-21,24-25H,3-19,22-23,26-29H2,1-2H3,(H2,37,39)(H,38,42)
| Molecular Formula | C36H59N5O2 |
| Molecular Weight | 593.886 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
MedImmune is developing MEDI 9197 (formerly 3M-052), a toll-like receptor 7/8 dual agonist, for the treatment of cancer. MEDI9197 has been designed to activate a broad range of innate immune cells through targeting of both TLR 7 and 8, leading to a more robust adaptive immune response. A TLR7 and 8 dual agonist can additionally convert immune suppressive cells in the tumor to those with anti-tumor properties, allowing the generation of an effective anti-tumor response. MEDI9197 is uniquely designed for intratumoral injection, allowing the compound to be retained in the tumor and provide specific immune activation, enhancing its safety and tolerability profile.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques. | 2019-02-21 |
|
| Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica. | 2018 |
|
| Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach. | 2016-12-28 |
|
| Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors. | 2014 |
Sample Use Guides
Mice: CT26 colon cancer cells were implanted subcutaneouslyinto the flank of syngeneic BALB/c mice. When these tumors reached 200 mm3 in volume, 100 ug of ODN and/or 50 ug of 3M-052 was injected intra-tumorally and the procedure repeated 2 days later.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:15:33 GMT 2025
by
admin
on
Mon Mar 31 21:15:33 GMT 2025
|
| Record UNII |
16598XQ2BT
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C2139
Created by
admin on Mon Mar 31 21:15:33 GMT 2025 , Edited by admin on Mon Mar 31 21:15:33 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
16598XQ2BT
Created by
admin on Mon Mar 31 21:15:33 GMT 2025 , Edited by admin on Mon Mar 31 21:15:33 GMT 2025
|
PRIMARY | |||
|
1359993-59-1
Created by
admin on Mon Mar 31 21:15:33 GMT 2025 , Edited by admin on Mon Mar 31 21:15:33 GMT 2025
|
PRIMARY | |||
|
SUB184743
Created by
admin on Mon Mar 31 21:15:33 GMT 2025 , Edited by admin on Mon Mar 31 21:15:33 GMT 2025
|
PRIMARY | |||
|
10781
Created by
admin on Mon Mar 31 21:15:33 GMT 2025 , Edited by admin on Mon Mar 31 21:15:33 GMT 2025
|
PRIMARY | |||
|
56833311
Created by
admin on Mon Mar 31 21:15:33 GMT 2025 , Edited by admin on Mon Mar 31 21:15:33 GMT 2025
|
PRIMARY | |||
|
C124653
Created by
admin on Mon Mar 31 21:15:33 GMT 2025 , Edited by admin on Mon Mar 31 21:15:33 GMT 2025
|
PRIMARY | |||
|
100000170639
Created by
admin on Mon Mar 31 21:15:33 GMT 2025 , Edited by admin on Mon Mar 31 21:15:33 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
|
||
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Direct activation of innate immune cells with anti-tumor activity was observed, as was a reduction in the immunosuppressive local environment. 3M-052 also induces the accumulation of mononuclear phagocytes concomitant with the induction of histologically established tumor liquifactive necrosis. Moreover, 3M-052 induces antitumor activity when injected into tumors but not when injected distal from tumors. These findings are based on inhibition of tumor growth and increased long-term survival. 3M-052 is under consideration for clinical use in patients with cancers suitable for intratumoral therapy and as being evaluated as a cancer vaccine adjuvant.
|
